FDA warned Premier Trends over manufacturing-quality failures and missing FDA registration/listing for its Magic Heal skin drug.
What happened
After an inspection from September 23 to September 29, 2021, at its Monroe Township, NJ facility, FDA found current good manufacturing practice (CGMP) failures, including releasing Magic Heal without testing batches or components, lacking equipment calibration, adequate batch records, training, and a quality unit. FDA also found the firm was not registered and had discontinued the Magic Heal drug listing on November 30, 2020, while continuing to manufacture it until at least the inspection. The firm's October 9, 2021, response was inadequate.
What FDA found
Failed to test each batch of Magic Heal for the identity and strength of active ingredients before release and lacked approved specifications.
21 CFR 211.165(a)Failed to test incoming components, including dimethicone active ingredient, neem oil, karanja oil, and lavender, for identity and quality, and relied on supplier test reports without validating them.
21 CFR 211.84(d)(1) and (2)Failed to calibrate or verify the temperature-controlled manufacturing equipment and the scale used to weigh drug components.
21 CFR 211.68(a)Failed to prepare adequate master and batch production records, which lacked approval signatures, detailed instructions, equipment identity, sampling information, and yield, and made process changes without justification or change control.
21 CFR 211.186(a) and 211.188Failed to establish a quality unit with authority to approve or reject components and drug products and to have written procedures for release, deviations, complaints, recalls, returns, and rejects.
21 CFR 211.22(a)Failed to register as a drug establishment and to keep Magic Heal listed with FDA, making its drugs misbranded.
FD&C Act sections 502(o) and 510(i)(1); 21 CFR 207.17 and 207.41
What FDA wants
FDA tells Premier Trends to correct the violations promptly and respond in writing within 15 working days describing actions taken and preventive steps. If it cannot finish within that time, it must give reasons and a completion schedule.
Who should pay attention
- brands and distributors selling OTC skin products
- contract manufacturers relying on supplier certificates of analysis
- drug establishments that must register and list products with FDA
This is a summary. Read the original letter on fda.gov.